scholarly journals Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)

Kidney Cancer ◽  
2017 ◽  
Vol 1 (1) ◽  
pp. 41-47 ◽  
Author(s):  
Steven M. Yip ◽  
Jose M. Ruiz Morales ◽  
Frede Donskov ◽  
Anna Fraccon ◽  
Umberto Basso ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Chromophobe Renal Cell Carcinoma ◽  
Metastatic Renal Cell Cancer

Nephrectomy Followed by Interferon Alfa-2b Compared With Interferon Alfa-2b Alone for Metastatic Renal Cell Cancer

2021 ◽  
pp. 113-118
Author(s):  
Christopher Weight
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Performance Status ◽  
Cell Cancer ◽  
Interferon Alfa ◽  
Cytoreductive Nephrectomy

This chapter summarizes the findings of a landmark trial of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma performed in the interferon era. All enrolled patients had a good performance status. It found overall survival extended by about 3 months in the cytoreductive-nephrectomy-plus-interferon arm versus the interferon-only arm.

scholarly journals The renal cell cancer database Sweden (RCCBaSe) – a new register-based resource for renal cell carcinoma research

2020 ◽  
Vol 54 (3) ◽  
pp. 235-240
Author(s):  
Anna Landberg ◽  
Per Lindblad ◽  
Ulrika Harmenberg ◽  
Sven Lundstam ◽  
Börje Ljungberg ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer

Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 519-519
Author(s):  
Mustafa Erman ◽  
Zafer Arik ◽  
Saadettin Kilickap ◽  
Cenk Yucel Bilen ◽  
Sertac Yazici ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Indirect Evidence ◽  
Cancer Center ◽  
Interferon Α ◽  
Targeted Agents ◽  
Metastatic Renal Cell Cancer ◽  
The Impact

519 Background: Though targeted agents have dramatically changed the outcome of metastatic renal cell cancer (mRCC) patients, it has not been possible to show any survival advantage, probably due to substantial cross-over in randomized trials. The change in survival times following the introduction of targeted agents may yield indirect evidence of an improvement in overall survival (OS). Methods: First targeted agents were available in Turkey in 2007. Data from the hospital charts of adult mRCC patients treated between January 2003 and December 2012 were included. Demographic and clinical findings along with patient, tumor, and treatment-related prognostic factors and their correlation with progression-free survival (PFS), and OS were analyzed. Results: One hundred and seventy six patients had metastatic disease. Of these, 107 patients received at least one dose of interferon-α and 74 patients received at least one targeted therapy. Median follow-up was 19.1 months (range 1-97 months) and median OS was 24.6 months (95% CI, 20.4-28.9). Median OS of patients who received any targeted therapy was significantly better than those who did not (29.1 mths [95% CI, 21.4-36.8] vs 19.4 mths [95% CI, 14.2-24.6]; p=0.036). The study period of 2003-2012 was subdivided into 4 consecutive groups. Although not statistically significant, a trend toward better survival was observed with advancing years and increasing targeted therapy use (p=0.09). For example, median OS of patients diagnosed in 2006 and 2007 was 14.1 months (95% CI, 10.4-17.8) while median OS of those diagnosed in 2010 or later was 30.8 months (95% CI, 18.3-43.3). Patients in intermediate and poor Memorial Sloan-Kettering Cancer Center risk groups benefited more from targeted therapies (p=0.001). Conclusions: Patients who received any targeted therapy lived longer than those who did not. Trend toward better survival was associated with advancing years and increasing targeted therapy use. The introduction of targeted agents appear to benefit mRCC patients in terms of OS as well.

Long survival (SV) for metastatic renal cell cancer (mRCC) after cytoreductive nephrectomy (CN) plus lung metastasectomy (LM) without targeted therapy (TT).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e16564-e16564
Author(s):  
Jose F. Corona-Cruz ◽  
Miguel Patricio Moscoso-Fernandez Salvador ◽  
Laura Alejandra Ramirez-Tirado ◽  
Josue Andres Gonzalez-Luna ◽  
Miguel A. Alvarez ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Cytoreductive Nephrectomy ◽  
Long Survival ◽  
Metastatic Renal Cell Cancer ◽  
Lung Metastasectomy

scholarly journals Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer

2017 ◽  
Vol 7 (4) ◽  
pp. 591-594 ◽  
Author(s):  
Senji Hoshi ◽  
Kenji Numahata ◽  
Hidenori Kanno ◽  
Masahiko Sato ◽  
Akihito Kuromoto ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Molecular Targeted Therapy ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer
Sign in / Sign up

Export Citation Format

Share Document